Management pieces in place
While the recent departure of its CEO may have come as a surprise to investors, the key parts of a transition to address Destiny Pharma’s next transactional deals may have been building to fruition for some time. Business development plus leadership of the Board and management teams are already now in place, with the focus on XF-73 remaining a constant.In a relatively short space of time, the interim CEO has given way to the permanent appointment of Chris Tovey, who will assume the position of Destiny’s CEO on September 1. Chris joins Destiny from Jazz Pharmaceuticals and GW Pharmaceuticals, and his involvement in the growth and major transactions of both companies should serve Destiny well at this time in its evolution.
After the appointment of its new CEO, Destiny announced the well-received appointment, or re-appointment, of its Chairman Sir Nigel Rudd who held the same position from 2010 until 2018 and presided over its IPO. Sir Nigel returns with the helpful gravitas of a UK industry grandee, and as a significant Destiny shareholder.
In the statements on their appointments, Debra Barker, Chris Tovey and Sir Nigel have all mentioned XF-73 and the US partnering opportunity. This should leave investors in no doubt of the focus of Destiny Pharma in the next year.
Our fair value for Destiny Pharma plc remains unchanged at £254.7m (or 279 pence per share).
Destiny Pharma is engaged in the discovery, development and commercialization of antimicrobials that have properties to improve outcomes for patients and the delivery of medical care into the future.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.